Abstract
In this Issue of Blood, Sargin and colleagues identify a mutation in the negative regulator c-Cbl in human acute myelold leukemia (AML) that mirrors the effects seen with oncogenic Flt3 receptors. Thus, an alternative mechanism for the inappropriate activation of receptor tyrosine kinases (RTKs) in tumors occurs through inactivation of a negative regulator.
| Original language | English |
|---|---|
| Pages (from-to) | 793-794 |
| Journal | Blood |
| Volume | 110 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2007 |